PURPOSE: A long-lasting, slow-release, crystalline antiviral drug delivery system was initially reported using ganciclovir and cyclic cidofovir as the prototype compounds. The present study was undertaken to investigate the feasibility of applying this system to antiproliferative small molecules. METHODS: The crystalline lipid prodrugs of hexadecyloxypropyl-arabinofuranosylguanine 5'-monophosphate (HDP-P-AraG), hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic 3',5'-monophosphate (HDP-cP-5-F-2dUrd), and hexadecyloxypropyl 5-fluoro-2'-deoxyuridine 5'-monophosphate (HDP-P-5-F-2dUrd) were synthesized from their parent compounds arabinofuranosylguanine (AraG) and 5-fluoro-2'-deoxyuridine (5-F-2dUrd). All three compounds were tested at escalating doses in rabbit eyes. Only one eye of each animal was injected with test compound, and the fellow eye was injected with 5% dextrose as the control. The injected eyes were monitored by slit lamp, a handheld tonometer, indirect ophthalmoscopy, electroretinography (ERG), and histology. The selected doses were used for efficacy study with the rat CNV model or the rabbit PVR model. RESULTS: The highest nontoxic dose for HDP-P-AraG was 75 microg/eye, and was 70 and 210 microg/eye for HDP-P-5-F-2dUrd and HDP-cP-5-F-2dUrd, respectively. All compounds demonstrated a localized depot of crystalline aggregate in the vitreous with a clear view of vitreous and retina elsewhere. The drug depot of HDP-P-AraG was visible for 4 to 5 weeks; HDP-P-5-F-2dUrd, 8 to 10 weeks; and HDP-cP-5-F-2dUrd longer than 14 weeks. The treatment study showed HDP-P-AraG led to 33% reduction in CNV in the rat (P = 0.015), and HDP-cP-5-F-2dUrd provided 100% prevention of trauma-induced PVR in the rabbit (P = 0.046). The pretreatment study demonstrated a significant protection against intraocular proliferation compared with the 5-FU in a parallel study (P = 0.014). CONCLUSIONS: The intravitreous injectable lipid prodrugs of AraG and 5-fluoro-2'-deoxyuridine could be long-lasting, slow-release, antiproliferative compounds to treat unwanted intraocular proliferation.
PURPOSE: A long-lasting, slow-release, crystalline antiviral drug delivery system was initially reported using ganciclovir and cyclic cidofovir as the prototype compounds. The present study was undertaken to investigate the feasibility of applying this system to antiproliferative small molecules. METHODS: The crystalline lipid prodrugs of hexadecyloxypropyl-arabinofuranosylguanine 5'-monophosphate (HDP-P-AraG), hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic 3',5'-monophosphate (HDP-cP-5-F-2dUrd), and hexadecyloxypropyl 5-fluoro-2'-deoxyuridine 5'-monophosphate (HDP-P-5-F-2dUrd) were synthesized from their parent compounds arabinofuranosylguanine (AraG) and 5-fluoro-2'-deoxyuridine (5-F-2dUrd). All three compounds were tested at escalating doses in rabbit eyes. Only one eye of each animal was injected with test compound, and the fellow eye was injected with 5% dextrose as the control. The injected eyes were monitored by slit lamp, a handheld tonometer, indirect ophthalmoscopy, electroretinography (ERG), and histology. The selected doses were used for efficacy study with the rat CNV model or the rabbit PVR model. RESULTS: The highest nontoxic dose for HDP-P-AraG was 75 microg/eye, and was 70 and 210 microg/eye for HDP-P-5-F-2dUrd and HDP-cP-5-F-2dUrd, respectively. All compounds demonstrated a localized depot of crystalline aggregate in the vitreous with a clear view of vitreous and retina elsewhere. The drug depot of HDP-P-AraG was visible for 4 to 5 weeks; HDP-P-5-F-2dUrd, 8 to 10 weeks; and HDP-cP-5-F-2dUrd longer than 14 weeks. The treatment study showed HDP-P-AraG led to 33% reduction in CNV in the rat (P = 0.015), and HDP-cP-5-F-2dUrd provided 100% prevention of trauma-induced PVR in the rabbit (P = 0.046). The pretreatment study demonstrated a significant protection against intraocular proliferation compared with the 5-FU in a parallel study (P = 0.014). CONCLUSIONS: The intravitreous injectable lipid prodrugs of AraG and 5-fluoro-2'-deoxyuridine could be long-lasting, slow-release, antiproliferative compounds to treat unwanted intraocular proliferation.
Authors: Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman Journal: Invest Ophthalmol Vis Sci Date: 2004-11 Impact factor: 4.799
Authors: J A Cardillo; M E Farah; J Mitre; P H Morales; R A Costa; L A S Melo; B Kuppermann; R Jorge; P Ashton Journal: Br J Ophthalmol Date: 2004-09 Impact factor: 4.638
Authors: Haiyan Wang; Jay Chhablani; William R Freeman; James R Beadle; Karl Y Hostetler; Kathrin Hartmann; Laura Conner; Kathy A Aldern; Lindsey Pearson; Lingyun Cheng Journal: Invest Ophthalmol Vis Sci Date: 2011-12-09 Impact factor: 4.799
Authors: Feiyan Ma; Kaihui Nan; SuNa Lee; James R Beadle; Huiyuan Hou; William R Freeman; Karl Y Hostetler; Lingyun Cheng Journal: Eur J Pharm Biopharm Date: 2014-12-13 Impact factor: 5.571
Authors: Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng Journal: Invest Ophthalmol Vis Sci Date: 2013-02-01 Impact factor: 4.799
Authors: Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng Journal: J Ocul Pharmacol Ther Date: 2013-02-28 Impact factor: 2.671
Authors: Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan Journal: Biomolecules Date: 2021-02-24
Authors: Mei Chen; Jiangping Hou; Guilin Tan; Peng Xie; William R Freeman; James R Beadle; Karl Y Hostetler; Lingyun Cheng Journal: Drug Deliv Date: 2017-11 Impact factor: 6.419